Found 1327 clinical trials
ADME Study of Acoziborole in Healthy Subjects
All subjects will receive an oral dose of 960 mg [14C] acoziborole on a single occasion as 4 capsules containing a small amount of radioactivity (not more than [NMT] 1000 nCi [37 KBq] 14C).
- 0 views
- 19 Feb, 2024
- 1 location
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer
This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy (SABR) plus nivolumab as neoadjuvant treatment in early-stage non-small cell lung cancer. The patients will receive standard SABR + nivolumab at a dose of 360 mg every 21 days for …
- 0 views
- 19 Feb, 2024
- 1 location
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression. Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used with other drugs in the treatment of some types of cancer. The …
- 0 views
- 19 Feb, 2024
- 1 location
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. This study will be used to define the recommended Phase 2 dose (RP2D).
- 0 views
- 19 Feb, 2024
- 2 locations
PHP and Immunotherapy in Metastasized UM
With this treatment combination we aim to find a treatment for disseminated uveal melanoma, both in the liver as in the other organs.
- 0 views
- 19 Feb, 2024
- 1 location
Do We Need to Taper Down Steroid Therapy for Bell's Palsy
Steroid-induced side effects generally require tapering of the drug as soon as the disease being treated is under control. Tapering must be done carefully to avoid both recurrent activity of the underlying disease and possible cortisol deficiency resulting from hypothalamic-pituitary-adrenal axis (HPA) suppression.
- 0 views
- 19 Feb, 2024
- 1 location
Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT
Recently, the evidence supports hippocampal avoidance with whole brain radiotherapy (HA-WBRT) as the recommended treatment option in patients with good prognosis and multiple brain metastases as it gives better neurocognitive preservation compared to historical whole brain radiotherapy controls.
- 0 views
- 19 Feb, 2024
- 1 location
Vaccine Responsiveness After CAR-T Cell Therapy
This phase I trial will use the inactivated rabies virus vaccine to assess immune function in patients who previously underwent B cell targeted chimeric antigen receptor-modified T cell immunotherapy (CARTx). A cohort of healthy volunteers will also be enrolled as a comparator group. CARTx is a new treatment for patients …
- 0 views
- 19 Feb, 2024
- 1 location
Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19
In this study, the samples will be selected from among patients with SARS-CoV-2 as easy access and based on entry criteria and will be randomly divided into two groups, including a control group and an intervention group.
- 0 views
- 19 Feb, 2024
- 1 location
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab
The treating neurologist must make an independent medical assessment and decision to initiate ocrelizumab treatment per label (USPI) as the most appropriate standard of care treatment for the participant. 150 participants will be enrolled in the main study (75 AA and 75 HA) and 50 participants will be enrolled in …
- 0 views
- 19 Feb, 2024
- 31 locations